Charles R. Harrington et al., 2015-03-10: Cell-model work reporting an intracellular Ki of 0.12 micromolar for methylthioninium tau-aggregation inhibition and linking it to the 0.13-0.18 micromolar brain concentrations that produced effects in mice and patients.
The Ki value for intracellular TAI activity, which we have been able to determine for the first time, is 0.12 μM.
Abstract
Charles R. Harrington et al., 2015-03-10: Cell-model work reporting an intracellular Ki of 0.12 micromolar for methylthioninium tau-aggregation inhibition and linking it to the 0.13-0.18 micromolar brain concentrations that produced effects in mice and patients. Laboratory cell models (two cell lines expressing tau fragments) plus PHF dissolution assays; no human subjects. Country: United Kingdom (TauRx Therapeutics / University of Aberdeen). Concentrations: LMTX salts disrupted AD-brain PHFs at 0.16 microM; intracellular Ki 0.12 microM; steady-state trough brain concentration 0.18 microM associated with arrested progression; minimum brain concentration 0.13 microM in tau transgenic mice. Route: in vitro / cell culture; brain concentrations from preclinical and clinical PK. Funder: 'Research Support, Non-U.S. Gov't' (TauRx). Conflicts: several authors are TauRx employees or shareholders – verifier should read the disclosure section; the paper does not declare this in the PubMed record. Comparator: untreated cells; native PHFs. This is the direct answer to the 'only at unachievable concentrations' objection – it is from the company that owns the drug, so it is recorded as such. Study type: lab.
